Mylan Overcomes Biogen Bid For Tecfidera Injunction
Generics Firm Is Facing Appeal Over 2028-Expiring Patent Win
Mylan is a step closer to realizing launch of a generic version of Biogen’s $3.3bn Tecfidera (dimethyl fumarate) multiple-sclerosis brand in the US after the originator was denied an injunction pending its appeal of an unfavorable patent decision at the district court level.
